Nath Bio-Genes (India) Ltd has announced the record date for its 33rd Annual General Meeting and dividend eligibility. Shareholders holding equity shares as of September 11, 2026 will be eligible to vote at the upcoming meeting and receive the declared dividend.

The company scheduled the 33rd AGM for Thursday, September 24, 2026 at 11:00 am. The meeting will be conducted through Video Conferencing or Other Audio Visual Means (VC/OAVM).

Regulatory Disclosure

The announcement was made pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure was issued to the BSE Limited and the National Stock Exchange of India Ltd.

Amol Gupta, Chief Financial Officer of Nath Bio-Genes (India) Ltd, signed the intimation on September 4, 2026.

Nath Bio-Genes (India) Limited reported a 12% year-on-year increase in standalone net profit to ₹32.66 crore for the quarter ended June 30, 2026, driven by a 15% surge in revenue from operations to ₹322.84 crore. The company’s consolidated net profit rose 14% YoY to ₹32.26 crore, while consolidated revenue grew 16% to ₹328.40 crore. This performance underscores strong demand in its seed cultivation segment during the first quarter of FY27, supported by robust operational execution and efficient margin management.

The Board of Directors approved the unaudited financial results at a meeting held on July 29, 2026, in compliance with Regulation 30, Regulation 33, and Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee on July 28, 2026. Gautam N Associates, the statutory auditors, issued a limited review report on both standalone and consolidated financial statements, confirming they present true and fair views in accordance with Ind AS 34.

Financial Performance

Standalone revenue from operations stood at ₹322.84 crore in Q1FY27, compared to ₹280.17 crore in the corresponding quarter of FY26. Total expenses were ₹28.88 crore, resulting in a profit from operations before other income and finance costs of ₹34.07 crore. Other income contributed ₹1.90 crore, while finance costs amounted to ₹3.79 crore. Exceptional items added ₹1.20 crore to the bottom line. After tax expenses of ₹0.72 crore, the standalone net profit reached ₹32.66 crore, up from ₹29.21 crore in Q1FY26. Earnings per share (basic and diluted) increased to ₹17.18 from ₹15.37 in the previous year.

On a consolidated basis, revenue from operations was ₹328.40 crore, compared to ₹283.70 crore in Q1FY26. Consolidated net profit was ₹32.26 crore, a significant improvement from ₹28.28 crore in the prior year period. Consolidated EPS rose to ₹16.98 from ₹14.88. The consolidation includes Nath Bio-Genes CA, Uzbekistan, where the company holds a 90% equity stake.

Strategic Positioning

The company highlighted its focus on R&D with a team of experienced scientists prioritizing disease and pest resistance breeding. It maintains a large and diverse collection of germplasm and operates well-invested, DSIR-recognized R&D innovation centers. The firm produces genetically pure and premium quality seeds, supported by cold storage facilities, warehouses, and conditioning godowns having a capacity of 25,000MT. The investor presentation emphasized growing business product excellence and differentiated customer experience through margin expansion and strong positions in important crops.

What the Numbers Show

The divergence between standalone and consolidated profitability highlights the impact of international operations. While standalone profit grew steadily, the consolidated figures reflect additional complexities from the Uzbekistan joint venture, including currency translation adjustments and specific local expenses. However, the consistent double-digit growth in both top-line revenue and bottom-line profit across both reporting bases indicates robust operational execution in the seed cultivation segment, which remains the company’s sole major product line.